SCHEMBL7477617

SCHEMBL7477617

Cn1cccc1CCC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 7/20 0.46
KEAP1 Q14145 1/20 0.45
HSD17B10 Q99714 5/20 0.44
ALOX15 P16050 2/20 0.44
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
RECQL P46063 1/20 0.43
HPGD P15428 3/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
FFAR1 O14842 2/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HDAC6 Q9UBN7 1/20 0.41
POLB P06746 2/20 0.41
GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13772975 0.89 SMN1; SMN2 (0.48) ALDH1A1RAB9ASMN1; SMN2HSD17B10CYP2C19
SCHEMBL13772976 0.86 TBXAS1 (0.52) ALDH1A1RAB9ASMN1; SMN2HDAC6MAPT
SCHEMBL11466037 0.85 ALDH1A1 (0.47) ALDH1A1RAB9ASMN1; SMN2KDM4ECYP2C19
SCHEMBL867896 0.80 ALDH1A1 (0.53) ALDH1A1RAB9ASMN1; SMN2KDM4ECYP2C19
SCHEMBL19051530 0.80 LMNA (0.54) ALDH1A1RAB9ASMN1; SMN2KDM4EHDAC6
SCHEMBL4600718 0.78 CYP4F2 (0.50) ALDH1A1SMN1; SMN2KDM4EHSD17B10GAA
SCHEMBL18979709 0.77 KEAP1 (0.41) ALDH1A1KDM4EKEAP1HSD17B10ALOX15
SCHEMBL28630338 0.76 ALDH1A1 (0.52) ALDH1A1RAB9ASMN1; SMN2KDM4ECYP2C19
SCHEMBL9645804 0.75 ALDH1A1 (0.51) ALDH1A1KDM4EKEAP1HSD17B10ALOX15
SCHEMBL4450606 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119040440-A Extended microscopic method suitable for protein and nucleic acid super-resolution co-imaging and application thereof 上海交通大学 2024-11-29 CN disclosed
EP-3700911-B1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2023-09-06 EP disclosed
EP-3700911-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier SAS (FR) 2020-09-02 EP disclosed
US-9981018-B2 Compositions and methods for modulating toll-like receptor 2 activation THE CLEVELAND CLINIC FOUNDATION (US) 2018-05-29 US disclosed
US-7560257-B2 Diagnostic methods for age related macular degeneration THE CLEVELAND CLINIC FOUNDATION (US) 2009-07-14 US disclosed
US-20080160505-A1 DIAGNOSTIC METHODS FOR AGE RELATED MACULAR DEGENERATION THE CLEVELAND CLINIC FOUNDATION 2008-07-03 US disclosed
US-7341839-B2 Diagnostic methods for age related macular degeneration THE CLEVELAND CLINIC FOUNDATION (US) 2008-03-11 US disclosed
US-20070072241-A1 diagnosing age-related macular degeneration comprising determining the level of anti-2-( omega -carboxyethyl) pyrrole (CEP) antibodies in a bodily fluid obtained from the test subject NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-03-29 US disclosed
US-7172874-B2 Diagnostic methods for age related macular degeneration THE CLEVELAND CLINIC FOUNDATION (US) 2007-02-06 US disclosed
EP-0800390-B1 CYCLOPROPYLPYRROLOINDOLE-OLIGOPEPTIDE ANTICANCER AGENTS UNIV ALBERTA (CA) 2002-12-04 EP disclosed
EP-0800390-A4 CYCLOPROPYLPYRROLOINDOLE-OLIGOPEPTIDE ANTICANCER AGENTS SYNPHAR LAB INC (CA) 1999-01-20 EP disclosed
EP-0800390-A1 CYCLOPROPYLPYRROLOINDOLE-OLIGOPEPTIDE ANTICANCER AGENTS SYNPHAR LABORATORIES INC. (CA) 1997-10-15 EP disclosed
WO-1996023497-A1 CYCLOPROPYLPYRROLOINDOLE-OLIGOPEPTIDE ANTICANCER AGENTS SYNPHAR LABORATORIES, INC. (CA) 1996-08-08 WO disclosed
US-5502068-A ABILITY TO ALKYLATE DNA SEQUENCES SYNPHAR LABORATORIES, INC. (CA) 1996-03-26 US disclosed